Next Article in Journal
hCG and Its Disruption by Environmental Contaminants during Human Pregnancy
Next Article in Special Issue
Pivotal Roles of Peroxisome Proliferator-Activated Receptors (PPARs) and Their Signal Cascade for Cellular and Whole-Body Energy Homeostasis
Previous Article in Journal
Suppression Effect of Astaxanthin on Osteoclast Formation In Vitro and Bone Loss In Vivo
Previous Article in Special Issue
Influence of Single-Nucleotide Polymorphisms in PPAR-δ, PPAR-γ, and PRKAA2 on the Changes in Anthropometric Indices and Blood Measurements through Exercise-Centered Lifestyle Intervention in Japanese Middle-Aged Men

PPARβ/δ: A Key Therapeutic Target in Metabolic Disorders

Pharmacology Unit, Department of Pharmacology, Toxicology and Therapeutic Chemistry, Institute of Biomedicine of the University of Barcelona (IBUB), Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain
Pediatric Research Institute-Hospital Sant Joan de Déu, 08950 Esplugues de Llobregat, Spain
Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, C/Monforte de Lemos 3-5, Pabellón 11, Planta 0, 28029 Madrid, Spain
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(3), 913;
Received: 29 January 2018 / Revised: 9 March 2018 / Accepted: 17 March 2018 / Published: 20 March 2018
(This article belongs to the Special Issue PPARs in Cellular and Whole Body Energy Metabolism)
Research in recent years on peroxisome proliferator-activated receptor (PPAR)β/δ indicates that it plays a key role in the maintenance of energy homeostasis, both at the cellular level and within the organism as a whole. PPARβ/δ activation might help prevent the development of metabolic disorders, including obesity, dyslipidaemia, type 2 diabetes mellitus and non-alcoholic fatty liver disease. This review highlights research findings on the PPARβ/δ regulation of energy metabolism and the development of diseases related to altered cellular and body metabolism. It also describes the potential of the pharmacological activation of PPARβ/δ as a treatment for human metabolic disorders. View Full-Text
Keywords: PPARβ/δ; obesity; dyslipidaemia; type 2 diabetes mellitus; non-alcoholic fatty liver disease PPARβ/δ; obesity; dyslipidaemia; type 2 diabetes mellitus; non-alcoholic fatty liver disease
Show Figures

Figure 1

MDPI and ACS Style

Palomer, X.; Barroso, E.; Pizarro-Delgado, J.; Peña, L.; Botteri, G.; Zarei, M.; Aguilar, D.; Montori-Grau, M.; Vázquez-Carrera, M. PPARβ/δ: A Key Therapeutic Target in Metabolic Disorders. Int. J. Mol. Sci. 2018, 19, 913.

AMA Style

Palomer X, Barroso E, Pizarro-Delgado J, Peña L, Botteri G, Zarei M, Aguilar D, Montori-Grau M, Vázquez-Carrera M. PPARβ/δ: A Key Therapeutic Target in Metabolic Disorders. International Journal of Molecular Sciences. 2018; 19(3):913.

Chicago/Turabian Style

Palomer, Xavier, Emma Barroso, Javier Pizarro-Delgado, Lucía Peña, Gaia Botteri, Mohammad Zarei, David Aguilar, Marta Montori-Grau, and Manuel Vázquez-Carrera. 2018. "PPARβ/δ: A Key Therapeutic Target in Metabolic Disorders" International Journal of Molecular Sciences 19, no. 3: 913.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop